NasdaqGS:GTHX

Stock Analysis Report

Executive Summary

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer.

Snowflake

Fundamentals

Flawless balance sheet with weak fundamentals.

Risks

  • G1 Therapeutics has significant price volatility in the past 3 months.

Share Price & News

How has G1 Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-7.0%

GTHX

0.3%

US Biotechs

-0.2%

US Market


1 Year Return

-37.2%

GTHX

-11.4%

US Biotechs

1.1%

US Market

GTHX underperformed the Biotechs industry which returned -11.3% over the past year.

GTHX underperformed the Market in United States of America which returned 1.6% over the past year.


Share holder returns

GTHXIndustryMarket
7 Day-7.0%0.3%-0.2%
30 Day-6.1%-1.9%2.5%
90 Day27.5%-2.4%1.6%
1 Year-37.2%-37.2%-10.7%-11.4%3.4%1.1%
3 Yearn/a5.0%1.4%45.2%35.8%
5 Yearn/a3.1%-1.9%62.6%44.8%

Price Volatility Vs. Market

How volatile is G1 Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is G1 Therapeutics undervalued based on future cash flows and its price relative to the stock market?

4.26x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for G1 Therapeutics to establish if it is available at moderate discount.

Unable to calculate intrinsic value for G1 Therapeutics to establish if it is available at substantial discount.


Price Based on Earnings

G1 Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.

G1 Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for G1 Therapeutics, we can't assess if its growth is good value.


Price Based on Value of Assets

G1 Therapeutics is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is G1 Therapeutics expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

7.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if G1 Therapeutics is high growth as no revenue estimate data is available.

G1 Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.

Unable to compare G1 Therapeutics's revenue growth to the United States of America market average as no estimate data is available.

Unable to compare G1 Therapeutics's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare G1 Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if G1 Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has G1 Therapeutics performed over the past 5 years?

-34.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

G1 Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare G1 Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare G1 Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if G1 Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if G1 Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if G1 Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is G1 Therapeutics's financial position?


Financial Position Analysis

G1 Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

G1 Therapeutics's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

G1 Therapeutics has no debt.

G1 Therapeutics has not taken on any debt in the past 5 years.


Balance Sheet

Low level of unsold assets.

G1 Therapeutics has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

G1 Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.

G1 Therapeutics has sufficient cash runway for 1.8 years if free cash flow continues to grow at historical rates of 42.9% each year.


Next Steps

Dividend

What is G1 Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate G1 Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate G1 Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as G1 Therapeutics has not reported any payouts.

Unable to verify if G1 Therapeutics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as G1 Therapeutics has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of G1 Therapeutics's salary, the management and board of directors tenure and is there insider trading?

1.7yrs

Average management tenure


CEO

Mark Velleca (55yo)

5.3yrs

Tenure

US$1,914,654

Compensation

Dr. Mark A. Velleca, M.D., Ph.D., has been Chief Executive Officer of G1 Therapeutics, Inc. since May 20, 2014 and has been its President since May 2014. Dr. Velleca served as Senior Advisor at Gilead Scie ...


CEO Compensation Analysis

Mark's remuneration is lower than average for companies of similar size in United States of America.

Mark's compensation has increased whilst company is loss making.


Management Age and Tenure

1.7yrs

Average Tenure

53.5yo

Average Age

The average tenure for the G1 Therapeutics management team is less than 2 years, this suggests a new team.


Board Age and Tenure

4.3yrs

Average Tenure

62yo

Average Age

The tenure for the G1 Therapeutics board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$26,19627 Dec 18
Cynthia Schwalm
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares1,420
Max PriceUS$18.45
BuyUS$18,25027 Dec 18
James Hanson
EntityIndividual
Role
Chief Legal Officer
General Counsel
Shares1,000
Max PriceUS$18.25
BuyUS$33,15111 Dec 18
John Demaree
EntityIndividual
Role
Senior Key Executive
Chief Commercial Officer
Shares1,000
Max PriceUS$33.15
BuyUS$32,50811 Dec 18
James Hanson
EntityIndividual
Role
Chief Legal Officer
General Counsel
Shares1,000
Max PriceUS$32.51

Ownership Breakdown


Management Team

  • Terry Murdock (59yo)

    Senior Vice President of Development Operations

    • Tenure: 2.1yrs
    • Compensation: US$2.75m
  • Mark Velleca (55yo)

    CEO, President & Director

    • Tenure: 5.3yrs
    • Compensation: US$1.91m
  • Lex Smith

    Vice President of Technical Operations

    • Tenure: 4.4yrs
  • Blake Jensen

    Vice President of Quality & Compliance

    • Tenure: 1.7yrs
  • Jay Strum (55yo)

    Chief Scientific Officer

    • Tenure: 10.7yrs
  • John Demaree (52yo)

    Chief Commercial Officer

    • Tenure: 1.2yrs
    • Compensation: US$7.47m
  • Jennifer Moses (44yo)

    Chief Financial Officer

    • Tenure: 0.3yrs
  • JoAnne Zellner

    Head of Human Resources

    • Tenure: 1.7yrs
  • Jeff Macdonald

    Head of Investor & Public Relations

    • Tenure: 1.7yrs
  • James Hanson (47yo)

    General Counsel

    • Tenure: 1.3yrs
    • Compensation: US$5.06m

Board Members

  • Seth Rudnick (70yo)

    Director & Member of Clinical Advisory Board

    • Tenure: 5.7yrs
    • Compensation: US$340.47k
  • Glenn Muir (60yo)

    Director

    • Tenure: 4yrs
    • Compensation: US$317.47k
  • Joseph Bailes (62yo)

    Scientific & Clinical Advisor

    • Tenure: 0yrs
  • Fred Eshelman (70yo)

    Director

    • Tenure: 4.6yrs
    • Compensation: US$304.97k
  • George Demetri (62yo)

    Scientific & Clinical Advisor

    • Tenure: 0yrs
  • Mark Velleca (55yo)

    CEO, President & Director

    • Tenure: 5.3yrs
    • Compensation: US$1.91m
  • Cynthia Schwalm (59yo)

    Independent Director

    • Tenure: 1.3yrs
    • Compensation: US$583.72k
  • Garry Nicholson (64yo)

    Chairman of the Board

    • Tenure: 0.3yrs
    • Compensation: US$922.81k
  • Kwok-Kin Wong

    Co-Founder & Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Geoffrey Shapiro

    Scientific & Clinical Advisor

    • Tenure: 0yrs

Company Information

G1 Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: G1 Therapeutics, Inc.
  • Ticker: GTHX
  • Exchange: NasdaqGS
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.334b
  • Shares outstanding: 37.52m
  • Website: https://www.g1therapeutics.com

Number of Employees


Location

  • G1 Therapeutics, Inc.
  • 79 T.W. Alexander Drive
  • Suite 100
  • Research Triangle Park
  • North Carolina
  • 27709
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GTHXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMay 2017
G1HDB (Deutsche Boerse AG)YesCommon StockDEEURMay 2017

Biography

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cance ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/20 01:20
End of Day Share Price2019/09/19 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.